Literature DB >> 10475404

Routine use of bilateral skeletonized internal mammary arteries for myocardial revascularization.

J Gurevitch1, Y Paz, I Shapira, M Matsa, A Kramer, D Pevni, O Lev-Ran, Y Moshkovitz, R Mohr.   

Abstract

BACKGROUND: Complete arterial myocardial revascularization without the use of saphenous veins grafts was primarily performed on selected patient populations such as the young and nondiabetic. In a recently developed surgical technique, the internal mammary artery is dissected gently as a longer skeletonized artery, providing greater versatility for complete arterial revascularization, without saphenous veins grafts.
METHODS: We prospectively evaluated the impact of the routine use of double skeletonized internal mammary artery in 472 patients who underwent coronary artery bypass grafting between April 1996 and June 1997. Their average age was 65 years (30 to 87 years), 383 (83%) were men, and 89 (17%) women. One hundred sixty-nine (36%) of the patients were older than 70 years, and 145 (31%) were diabetic. The average number of grafts was 3.2 per patient (two to six grafts).
RESULTS: Operative mortality was 1.7% (n = 8). The mortality of urgent and elective patients was 0.7% (3 of 410 patients), and that of emergency operations was 8.1% (5 of 62 patients; p < 0.01). There were three (0.6%) perioperative infarcts, and 6 patients (1.3%) sustained strokes. Sternal wound infection occurred in 8 patients (1.7%). Postoperative follow-up (1 to 25 months) was available in 462 patients (99%). Two-year actuarial survival was 96.8%, and 92% of the surviving patients are well and free of angina. Neither diabetes mellitus nor old age (>70 years) were significant independent predictors of any early or late untoward events. None of the 70 diabetic patients more than 65 years of age developed sternal wound infection. Chronic lung disease was found to be the only independent predictor for sternal infections.
CONCLUSIONS: Routine use of bilateral skeletonized internal mammary artery is a safe replacement for the current myocardial revascularization technique even in the old and diabetic patients.

Entities:  

Mesh:

Year:  1999        PMID: 10475404     DOI: 10.1016/s0003-4975(99)00460-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Bilateral internal mammary artery grafting: are BIMA better?

Authors:  D P Taggart
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

2.  Early and late outcome of skeletonised bilateral internal mammary arteries anastomosed to the left coronary system.

Authors:  M Bonacchi; F Battaglia; E Prifti; M Leacche; N S Nathan; G Sani; G Popoff
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

3.  Perioperative and clinical-angiographic late outcome of total arterial myocardial revascularization according to different composite original graft techniques.

Authors:  Massimo Bonacchi; Edvin Prifti; Massimo Maiani; Giacomo Frati; Gabriele Giunti; Marco Di Eusanio; Giuseppe Di Eusanio; Marzia Leacche
Journal:  Heart Vessels       Date:  2006-03       Impact factor: 2.037

4.  Influence of bilateral skeletonized harvesting on occurrence of deep sternal wound infection in 1,000 consecutive patients undergoing bilateral internal thoracic artery grafting.

Authors:  Dmitry Pevni; Rephael Mohr; Oren Lev-Run; Chaim Locer; Yosef Paz; Amir Kramer; Itzhak Shapira
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

5.  Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal mammary grafting in coronary revascularisation [ISRCTN46552265].

Authors:  David P Taggart; Belinda Lees; Alastair Gray; Douglas G Altman; Marcus Flather; Keith Channon
Journal:  Trials       Date:  2006-03-30       Impact factor: 2.279

6.  Risk factors for mediastinitis after cardiac surgery - a retrospective analysis of 1700 patients.

Authors:  Claudius Diez; Daniel Koch; Oliver Kuss; Rolf-Edgar Silber; Ivar Friedrich; Jochen Boergermann
Journal:  J Cardiothorac Surg       Date:  2007-05-20       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.